Moderna's Flu Vaccine Surge: A Chasm Between Market Hype and Wall Street's Skepticism

Related Articles

Did Moderna's Q4 Earnings Beat Outweigh the Flu Vaccine Setback

6 months ago

Is the "Absurd" Gap Between Retail and Wall Street Finally Closing

6 months ago

Why is Wall Street Bullish on GE Aerospace

6 months ago

Why Wall Street Is Betting Big on $5,000 Gold

9 months ago

Category

You may also like

Stock News•1 week ago

Moderna: Massive Asymmetry About What The mRNA Is!

Moderna received a speculative Strong Buy rating after phase 3 melanoma data strengthened its oncology platform thesis. Upside hinges on Intismeran scaling across tumor types via its 50/50 Merck partn...

MRNA

Share

Stock News•1 months ago

Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future

Moderna's stock rose after the FDA approved its mRNA flu vaccine, mFlusiva, for adults 50 and older, offering a new growth avenue beyond COVID-19.

MRNA

Share

Stock News•1 months ago

Moderna misses quarterly revenue estimates on COVID vaccine weakness

Moderna missed Q2 revenue estimates on Friday, hit by weaker-than-expected COVID-19 vaccine sales, ahead of an FDA decision on its experimental flu shot.

MRNA

Share